Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention relates to novel processes for the preparation of 3-methylenecephams. More specifically, the present invention relates to the intramolecular cyclization of penicillin sulfoxide derived monocyclic azetidinone derivatives with organometallic catalysts of the formula III. MEx(H2O)y  (III) wherein: M is Sc, Y, La, Ce, Pr, Nd, Sm, Eu, Gd, Tb, Dy, Ho, Er, Tm, Yb, Lu, Zr, Hf, Th, Nb, Ta, U, Bi, or In; E is O[SO2(C1-C6 polyfluoroalkyl)], N[SO2(C1-C6 polyfluoroalkyl)]2, or C[SO2(C1-C6 polyfluoroalkyl)]3; x is 3; y is 0, 1, 2, 3, 4, 5, 6, 7, 8, or 9.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective &bgr;3 receptor agonists useful in the treatment of Type II diabetes and obesity. The invention provides compounds and methods of treating type II diabetes and obesity, comprising administering to a mammal in need thereof compounds of the Formula I: or pharmaceutically acceptable salts thereof.

Abstract: A fertilizer composition that includes a plurality of particles in which the particles feature a plurality of sulfur platelets embedded within a fertilizer portion, and a method for preparing this composition in which fertilizer-containing particles are sprayed first with a sulfur spray, and then with a slurry containing fertilizer or a precursor thereof, followed by curing.

Abstract: Disclosed herein are selective beta 3 adrenergic agonists represented by the following structural formula: The variables in the structural formula shown above are defined in the specification. Also disclosed are methods of using these compounds for agonizing the beta 3 adrenergic receptor in patients in need of such treatment, for example, patients in need of treatment for obesity or Type II diabetes.

Abstract: A bar product prepared from microalloyed bar steel is provided. The bar product is prepared by hot rolling and heat treating a microalloyed bar steel. The hot rolled and heat treated microalloyed bar steel is prepared by steps of hot rolling a preform of the microalloyed bar steel at a temperature of between about 1,400° F. and about 2,200° F. to provide a steel bar having a diameter of between about ¾ inch and about four inches, cooling the steel bar to provide a surface temperature of below about 1,100° F., and heat treating the steel bar in an environment having a temperature of between about 500° F. and about 1,300° F. The bar product is preferably prepared without a step of cold drawing. In particular, the bar product is preferably prepared without a step of drawing to provide a 10% to a 35% reduction.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.

Abstract: The present invention is in the field of medicine, particularly in the treatment of Type II diabetes and obesity. More specifically, the present invention relates to selective .beta.3 adrenergic receptor agonists useful in the treatment of Type II diabetes and obesity.